EA201070127A1 - Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления - Google Patents
Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществленияInfo
- Publication number
- EA201070127A1 EA201070127A1 EA201070127A EA201070127A EA201070127A1 EA 201070127 A1 EA201070127 A1 EA 201070127A1 EA 201070127 A EA201070127 A EA 201070127A EA 201070127 A EA201070127 A EA 201070127A EA 201070127 A1 EA201070127 A1 EA 201070127A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- related diseases
- pulmonary hypertension
- disorders
- compositions
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 2
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 abstract 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 abstract 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Комбинации, включающие ингибитор триптофангидроксилазы, которые предназначены для лечения легочной гипертензии и родственных заболеваний.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94904007P | 2007-07-11 | 2007-07-11 | |
PCT/US2008/069471 WO2009009561A1 (en) | 2007-07-11 | 2008-07-09 | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201070127A1 true EA201070127A1 (ru) | 2010-08-30 |
Family
ID=39730871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201070127A EA201070127A1 (ru) | 2007-07-11 | 2008-07-09 | Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления |
Country Status (10)
Country | Link |
---|---|
US (3) | US7875622B2 (ru) |
EP (1) | EP2170397A1 (ru) |
JP (1) | JP2010533196A (ru) |
KR (1) | KR20100046189A (ru) |
CN (1) | CN101815534A (ru) |
AU (1) | AU2008275179B2 (ru) |
BR (1) | BRPI0814105A2 (ru) |
CA (1) | CA2693400A1 (ru) |
EA (1) | EA201070127A1 (ru) |
WO (1) | WO2009009561A1 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA019879B1 (ru) * | 2005-12-29 | 2014-07-30 | Лексикон Фармасьютикалз, Инк. | Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные |
MX2009013982A (es) * | 2007-06-26 | 2010-04-09 | Lexicon Pharmaceuticals Inc | Composiciones que comprenden inhibidores de triptofano hidroxilasa. |
CA2691003A1 (en) * | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
WO2009009561A1 (en) | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
MX2010010799A (es) * | 2008-03-31 | 2011-03-25 | Univ Columbia | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. |
US8815883B2 (en) | 2009-11-02 | 2014-08-26 | The Trustees Of Columbia Unviersity In The City Of New York | Compounds and methods for inhibiting serotonin synthesis |
TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
EP2582666B1 (en) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
US20130303763A1 (en) | 2012-03-30 | 2013-11-14 | Michael D. Gershon | Methods and compositions for the treatment of necrotizing enterocolitis |
EP2943479B1 (en) | 2013-01-11 | 2020-04-15 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
JP6227673B2 (ja) * | 2013-12-17 | 2017-11-08 | ステラファーマ株式会社 | 2−フルオロ−4−ボロノ−l−フェニルアラニンの製造方法および2−フルオロ−4−ボロノ−l−フェニルアラニンの前駆体 |
EP3169660A1 (en) | 2014-07-16 | 2017-05-24 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
TW201818964A (zh) | 2016-09-30 | 2018-06-01 | 瑞士商諾伊曼特醫療公司 | 使用色胺酸羥化酶抑制劑之方法 |
EP3674303B1 (en) * | 2017-08-24 | 2022-07-20 | Gwangju Institute of Science and Technology | Novel tryptophan hydroxylase inhibitor and pharmaceutical composition including same |
WO2020099926A1 (en) | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
EP3917531A1 (en) | 2019-01-30 | 2021-12-08 | Altavant Sciences GmbH | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4156734A (en) | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
EP0484437A4 (en) | 1989-07-27 | 1994-06-01 | Searle & Co | Renal-selective prodrugs for the treatment of hypertension |
JP2001517246A (ja) | 1997-06-23 | 2001-10-02 | 田辺製薬株式会社 | α▲下4▼β▲下1▼媒介細胞接着の阻止剤 |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
AU780385B2 (en) | 1999-09-24 | 2005-03-17 | Genentech Inc. | Tyrosine derivatives |
TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
WO2004017993A1 (en) | 2002-08-12 | 2004-03-04 | Actelion Pharmaceuticals Ltd | Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
AU2003272007A1 (en) | 2002-10-25 | 2004-05-13 | The Administrators Of The Tulane Educational Fund | Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
CA2509565A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
US6794401B2 (en) | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
JPWO2005044780A1 (ja) | 2003-11-10 | 2007-05-17 | 杏林製薬株式会社 | アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤 |
JP2007532681A (ja) | 2004-04-16 | 2007-11-15 | ジェネンテック・インコーポレーテッド | B細胞の枯渇を増大させる方法 |
EA019879B1 (ru) | 2005-12-29 | 2014-07-30 | Лексикон Фармасьютикалз, Инк. | Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные |
US7855291B2 (en) | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
JP2010512414A (ja) | 2006-12-12 | 2010-04-22 | ギリード・コロラド・インコーポレーテッド | 肺高血圧を処置するための組成物 |
CA2691003A1 (en) | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
WO2009009561A1 (en) | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
-
2008
- 2008-07-09 WO PCT/US2008/069471 patent/WO2009009561A1/en active Application Filing
- 2008-07-09 CN CN200880024101A patent/CN101815534A/zh active Pending
- 2008-07-09 KR KR1020107002983A patent/KR20100046189A/ko not_active Application Discontinuation
- 2008-07-09 EA EA201070127A patent/EA201070127A1/ru unknown
- 2008-07-09 CA CA2693400A patent/CA2693400A1/en not_active Abandoned
- 2008-07-09 BR BRPI0814105-3A2A patent/BRPI0814105A2/pt not_active Application Discontinuation
- 2008-07-09 JP JP2010516210A patent/JP2010533196A/ja active Pending
- 2008-07-09 AU AU2008275179A patent/AU2008275179B2/en not_active Ceased
- 2008-07-09 EP EP08826306A patent/EP2170397A1/en not_active Withdrawn
- 2008-07-09 US US12/169,815 patent/US7875622B2/en active Active
-
2011
- 2011-01-14 US US13/006,592 patent/US8410121B2/en active Active
-
2013
- 2013-03-18 US US13/845,533 patent/US20130274261A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2693400A1 (en) | 2009-01-15 |
AU2008275179A1 (en) | 2009-01-15 |
WO2009009561A1 (en) | 2009-01-15 |
EP2170397A1 (en) | 2010-04-07 |
JP2010533196A (ja) | 2010-10-21 |
US20110112094A1 (en) | 2011-05-12 |
KR20100046189A (ko) | 2010-05-06 |
BRPI0814105A2 (pt) | 2015-02-03 |
US20090054308A1 (en) | 2009-02-26 |
US8410121B2 (en) | 2013-04-02 |
US20130274261A1 (en) | 2013-10-17 |
AU2008275179B2 (en) | 2013-09-12 |
CN101815534A (zh) | 2010-08-25 |
US7875622B2 (en) | 2011-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201070127A1 (ru) | Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления | |
CY1117317T1 (el) | Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων | |
CY1120617T1 (el) | 1,2,5-οξαδιαζολια ως αναστολεις 2,3-διοξυγενασης ινδολοαμινης | |
CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
ATE502921T1 (de) | Substituierte indole | |
EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
EA201000094A1 (ru) | Производные пиримидинил-пиридазинона | |
DK1836169T3 (da) | Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser | |
EA201070058A1 (ru) | Способы лечения опосредованных серотонином заболеваний и расстройств | |
EA201171081A1 (ru) | Производные индола в качестве антагонистов рецептора crth2 | |
CY2016017I2 (el) | Συνθεση για θεραπεια πνευμονικης υπερτασης | |
EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
NO20074431L (no) | Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
EA201290894A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
ATE493986T1 (de) | Diarylharnstoffe zur behandlung von pulmonaler hypertonie | |
EA201070256A1 (ru) | Способ и промежуточные соединения для получения ингибиторов интегразы | |
ATE497961T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
EA200802072A1 (ru) | Ликопин для лечения нарушения обмена веществ |